BIOGEN INC

NASDAQ: BIIB (Biogen Inc.)

Last update: 05 Aug, 5:43PM

132.89

0.69 (0.52%)

Previous Close 132.20
Open 131.65
Volume 1,323,863
Avg. Volume (3M) 1,498,248
Market Cap 19,483,668,480
Price / Earnings (TTM) 12.73
Price / Earnings (Forward) 9.23
Price / Sales 1.93
Price / Book 1.10
52 Weeks Range
110.04 (-17%) — 207.59 (56%)
Earnings Date 29 Oct 2025
Profit Margin 15.07%
Operating Margin (TTM) 28.05%
Diluted EPS (TTM) 10.12
Quarterly Revenue Growth (YOY) 6.10%
Quarterly Earnings Growth (YOY) -38.90%
Total Debt/Equity (MRQ) 39.00%
Current Ratio (MRQ) 1.44
Operating Cash Flow (TTM) 2.58 B
Levered Free Cash Flow (TTM) 3.43 B
Return on Assets (TTM) 5.43%
Return on Equity (TTM) 9.19%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Biogen Inc. Bearish Bearish

AIStockmoo Score

-0.5
Analyst Consensus -0.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators 0.5
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BIIB 19 B - 12.73 1.10
AZN 226 B 1.44% 29.27 5.54
SNY 118 B 4.58% 16.37 1.48
AMGN 159 B 3.13% 24.16 20.85
GILD 141 B 2.08% 23.78 7.12
GRFS 6 B 1.73% 28.00 1.13

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Mid Value
% Held by Insiders 0.19%
% Held by Institutions 92.79%
52 Weeks Range
110.04 (-17%) — 207.59 (56%)
Price Target Range
118.00 (-11%) — 219.00 (64%)
High 219.00 (RBC Capital, 64.80%) Buy
Median 139.50 (4.97%)
Low 118.00 (Piper Sandler, -11.21%) Hold
Average 155.17 (16.77%)
Total 2 Buy, 4 Hold
Avg. Price @ Call 132.51
Firm Date Target Price Call Price @ Call
Piper Sandler 14 Aug 2025 118.00 (-11.20%) Hold 134.94
12 Jun 2025 115.00 (-13.46%) Hold 132.31
Citigroup 01 Aug 2025 135.00 (1.59%) Hold 131.95
HC Wainwright & Co. 01 Aug 2025 194.00 (45.99%) Buy 131.95
26 Jun 2025 187.00 (40.72%) Buy 126.92
Morgan Stanley 01 Aug 2025 144.00 (8.36%) Hold 131.95
RBC Capital 01 Aug 2025 219.00 (64.80%) Buy 131.95
27 Jun 2025 213.00 (60.28%) Buy 126.08
Wedbush 12 Jun 2025 121.00 (-8.95%) Hold 132.31

No data within this time range.

Date Type Details
02 Sep 2025 Announcement Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
02 Sep 2025 Announcement Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
02 Sep 2025 Announcement Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
29 Aug 2025 Announcement FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
29 Aug 2025 Announcement FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
29 Aug 2025 Announcement FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
25 Aug 2025 Announcement Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
25 Aug 2025 Announcement Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
25 Aug 2025 Announcement Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25 Aug 2025 Announcement Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25 Aug 2025 Announcement Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
11 Aug 2025 Announcement Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
11 Aug 2025 Announcement Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
30 Jul 2025 Announcement Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
30 Jul 2025 Announcement Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
30 Jul 2025 Announcement Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
30 Jul 2025 Announcement New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
25 Jul 2025 Announcement ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
25 Jul 2025 Announcement ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
21 Jul 2025 Announcement Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
21 Jul 2025 CNBC FDA taps biotech industry veteran as RFK Jr.'s top drug regulator 
21 Jul 2025 Announcement Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
21 Jul 2025 Announcement Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
10 Jul 2025 Announcement Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
10 Jul 2025 Announcement Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
10 Jul 2025 Announcement Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
30 Jun 2025 Announcement Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
30 Jun 2025 Announcement Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
27 Jun 2025 Announcement New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
27 Jun 2025 Announcement New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
25 Jun 2025 Announcement Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
25 Jun 2025 Announcement Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
18 Jun 2025 Announcement Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
18 Jun 2025 Announcement Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
12 Jun 2025 Announcement Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
12 Jun 2025 Announcement Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria